MYC and lymphoma: More recently, in a very large series of such lymphomas, the Lunenburg Lymphoma Biomarker Consortium could show that this poor outcome is actually restricted to DH/TH lymphomas with an IG-partner to the MYC rearrangement, while all other contexts (MYC-single hit, non-IG partners) have a similar outcome to DLBCL without a MYC rearrangement37.